Completed

Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

citalopram hydrobromide

+ placebo

DrugOther
Who is being recruted

Autism Spectrum Disorder+2

+ Autistic Disorder

+ Mental Disorders

From 5 to 17 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 2
Interventional
Study Start: April 2004
See protocol details

Summary

Principal SponsorBoston University
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2004

Actual date on which the first participant was enrolled.

For children with autism spectrum disorders (ASD, also known as Pervasive Developmental Disorders - PDDs), repetitive behaviors are common and frequently interfere with functioning in the home as well as in social and educational settings. These behaviors may involve repetitive movements, rigid routines, repetitive play, and even repetitive speech. These behaviors may be associated with high levels of anxiety, severe tantrums. Self-injury can occur when these behaviors and routines are interrupted. Participants will be randomly assigned to receive citalopram or placebo (administered as liquid), and carefully followed every two weeks. At the end of 12 weeks, children who have responded to treatment will be given the opportunity to continue in the study, with monthly visits, for an additional 24 weeks. Children who received placebo and did not respond to treatment at 12 weeks will be given the opportunity to receive a carefully monitored 12 week course of citalopram.

Official TitleCitalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior 
NCT00086645
Principal SponsorBoston University
Last updated: January 18, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

149 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 5 to 17 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Autism Spectrum DisorderAutistic DisorderMental DisordersChild Development Disorders, PervasiveNeurodevelopmental Disorders

Criteria

Inclusion Criteria: * Able to walk * Diagnosis of Autistic Disorder, Asperger's Disorder, or PDD-NOS * Have a score greater than or equal to (\>) 8 on the sum of items 1A, 2, 3 and 5 of the Compulsions Subscale of the Revised CYBOCS. * Have a rating of at least moderate behavioral disturbance based on the modified Clinical Global Impression-Severity of Illness score (CGI-S) at the time of screening (See description below). * Be free of psychotropic medication for at least one month for fluoxetine, two weeks for other SSRIs and neuroleptics, and for 5 days for stimulants prior to baseline ratings. * Be judged reliable for medication compliance and agree to keep appointments for study contacts and tests as outlined in the protocol (both subject and guardian(s)). Exclusion Criteria: * Medical contraindications to therapy with SSRIs * Prior exposure to citalopram (or escitalopram) of sufficient dose or duration to determine response status * History of treatment failure to a clinically adequate trial of two select SSRIs * Diagnosis of Rett's Disorder or Childhood Disintegrative Disorder * Uncontrolled epilepsy, with a seizure within past 6 months * Child weighs less than (\<) 15 kg at screening contact. * Pregnancy * Presence of chronic medical conditions that might interfere with study participation or where study participation would be contraindicated * Clinically significant abnormal baseline laboratory testing * History of bipolar disorder or manic episode induced by antidepressant exposure * Documented need for ongoing psychotropic medications besides study medication (with the exception of stable dose (at least 3 month) anti-convulsants for seizures). * Concomitant medication that would interfere with participation in the study. * Recent (\< 2 months) initiation of behavior therapy (such as parent training, applied behavior analysis or behavior modification) in a clinic, with a private practitioner or in a school program. Participants who are in an established behavior therapy program (defined as greater than (\>) 2 months for clinic or private practitioner or greater than (\>) 1 month for school program) can be included in the study. Families will be asked not to initiate any new behavior therapy during the study.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
citalopram hydrobromide, up to 20 mg daily

Group II

Placebo
placebo, up to equivalent of 20 mg of active comparator daily

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 6 locations

Suspended

UCLA Neuropsychiatric Institute

Los Angeles, United StatesSee the location
Suspended

Yale University

New Haven, United States
Suspended

Dartmouth-Hitchcock Medical Center

Lebanon, United States
Suspended

North Shore - Long Island Jewish Hospital

Great Neck, United States
Completed6 Study Centers